Nature Communications (Feb 2021)
Patient-derived xenografts and organoids model therapy response in prostate cancer
- Sofia Karkampouna,
- Federico La Manna,
- Andrej Benjak,
- Mirjam Kiener,
- Marta De Menna,
- Eugenio Zoni,
- Joël Grosjean,
- Irena Klima,
- Andrea Garofoli,
- Marco Bolis,
- Arianna Vallerga,
- Jean-Philippe Theurillat,
- Maria R. De Filippo,
- Vera Genitsch,
- David Keller,
- Tijmen H. Booij,
- Christian U. Stirnimann,
- Kenneth Eng,
- Andrea Sboner,
- Charlotte K. Y. Ng,
- Salvatore Piscuoglio,
- Peter C. Gray,
- Martin Spahn,
- Mark A. Rubin,
- George N. Thalmann,
- Marianna Kruithof-de Julio
Affiliations
- Sofia Karkampouna
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Federico La Manna
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Andrej Benjak
- Department for BioMedical Research, Oncogenomics Laboratory, University of Bern
- Mirjam Kiener
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Marta De Menna
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Eugenio Zoni
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Joël Grosjean
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Irena Klima
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Andrea Garofoli
- Institute of Pathology, University Hospital Basel, University of Basel
- Marco Bolis
- Institute of Oncology Research, Università della Svizzera italiana
- Arianna Vallerga
- Institute of Oncology Research, Università della Svizzera italiana
- Jean-Philippe Theurillat
- Institute of Oncology Research, Università della Svizzera italiana
- Maria R. De Filippo
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Vera Genitsch
- Institute of Pathology, University of Bern
- David Keller
- NEXUS Personalized Health Technologies, ETH Zurich
- Tijmen H. Booij
- NEXUS Personalized Health Technologies, ETH Zurich
- Christian U. Stirnimann
- NEXUS Personalized Health Technologies, ETH Zurich
- Kenneth Eng
- Department of Physiology and Biophysics, Institute for Precision Medicine and Englander Institute for Precision Medicine, Weill Cornell Medicine
- Andrea Sboner
- Department of Pathology and Laboratory Medicine, Institute for Computational Biomedicine, Englander Institute for Precision Medicine, Weill Cornell Medicine
- Charlotte K. Y. Ng
- Department for BioMedical Research, Oncogenomics Laboratory, University of Bern
- Salvatore Piscuoglio
- Institute of Pathology, University Hospital Basel, University of Basel
- Peter C. Gray
- The Salk Institute for Biological Studies
- Martin Spahn
- Lindenhofspital
- Mark A. Rubin
- Department for BioMedical Research, Precision Oncology Laboratory, University of Bern
- George N. Thalmann
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- Marianna Kruithof-de Julio
- Department for BioMedical Research, Urology Research Laboratory, University of Bern
- DOI
- https://doi.org/10.1038/s41467-021-21300-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
To date, patients still succumb to cancer, due to tumors not responding to therapy or ultimately acquiring resistance. Here the authors show that by exploiting patient derived organoids and a treatment-naïve patient derived xenograft, patient therapy can be personalized.
